732. Allogeneic Transplantation: Disease Response and Comparative Treatment Studies: Poster I

Efficacy of the triplet therapy with venetoclax, azacitidine and gilteritinib for the treatment of FLT3-ITD mutated AML patients with refractory/relapsed disease

Mismatched unrelated and haploidentical transplant with post transplant cyclophosphamide based graft versus host disease prophylaxis are effective for myelofibrosis

Matched sibling donors still provide superior survival outcomes in older patients with AML in second complete remission a study from the global committee and the acute leukemia working party of the european society for blood and marrow transplantation

Enhanced chimerism detection with multiple single Nucleotide Polymorphism Sequencing Improving risk stratification post allogeneic hematopoietic stem cell transplantation

Comparable outcomes of haploidentical sibling and unrelated donor transplantation for adult T ALL in second remission  a study from the global committee and ALWP of the EBMT

Impact of TBI donor age and transplant era on outcomes of allogeneic transplantation in acute lymphoblastic leukemia Evidence from 748 patients in Latin America

TP53 EZH2 or RUNX1 mutations predict poor outcomes in ELN 2022 adverse risk group of adult AML patients undergoing allo HSCT

Blinatumomab before and after allogeneic hematopoietic stem cell transplantation in adult patients with B cell acute lymphoblastic leukemia

Autologous stem cell transplantation versus consolidation chemotherapy as post remission treatment in newly diagnosed favorable and intermediate risk patients with AML A comparative analysis of HOVON SAKK Nordic trials

Sustained donor engraftment and clinical remission after hematopoietic cell transplantation for vexas syndrome but with observed toxicities Results from a prospective phase II clinical Trial

Serum albumin but not gnri is an independent prognostic factor for survival after first allogeneic SCT A large scale multicenter analysis

Superior outcome from frontline cord blood transfusion combined HLA full matched unrelated donor hematopoietic stem cell transplantation for aplastic anemia